A few years ago, the oncology world wondered if it had found its next big breakthrough: a third major checkpoint inhibitor beyond PD-1 and CTLA-4.
The FDA in 2022 …
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate
A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints
AstraZeneca’s cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
CirCode Biomed, a Chinese startup working on an experimental class of genetic medicines known as circular RNA, has received the FDA’s blessing to begin a
A few years ago, the oncology world wondered if it had found its next big breakthrough: a third major checkpoint inhibitor beyond PD-1 and CTLA-4.
The FDA in 2022 …